Kornblau SM - Search Results

1

EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Kampen KR, Scherpen FJ, Garcia-Manero G, Yang H, Kaspers GJ, Cloos J, Zwaan CM, van den Heuvel-Eibrink MM, Kornblau SM, De Bont ES. Kampen KR, et al. Among authors: kornblau sm. Mol Cancer Res. 2015 Jun;13(6):982-92. doi: 10.1158/1541-7786.MCR-14-0660-T. Epub 2015 May 5. Mol Cancer Res. 2015. PMID: 25944917 Free PMC article.

2

Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia.

Kornblau SM, Xu HJ, del Giglio A, Hu SX, Zhang W, Calvert L, Beran M, Estey E, Andreeff M, Trujillo J, et al. Kornblau SM, et al. Cancer Res. 1992 Sep 1;52(17):4587-90. Cancer Res. 1992. PMID: 1511426

3

Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia.

Kornblau SM, Xu HJ, Zhang W, Hu SX, Beran M, Smith TL, Hester J, Estey E, Benedict WF, Deisseroth AB. Kornblau SM, et al. Blood. 1994 Jul 1;84(1):256-61. Blood. 1994. PMID: 8018920 Free article.

4

Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia.

Kornblau SM, Chen N, del Giglio A, O'Brien S, Deisseroth AB. Kornblau SM, et al. Cancer Res. 1994 Jan 1;54(1):242-6. Cancer Res. 1994. PMID: 8261446

5

High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia.

Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. Zhang W, et al. Among authors: kornblau sm. Clin Cancer Res. 1995 Sep;1(9):1051-7. Clin Cancer Res. 1995. PMID: 9816079

6

The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.

Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. Kornblau SM, et al. Clin Cancer Res. 1999 Jul;5(7):1758-66. Clin Cancer Res. 1999. PMID: 10430080

7

Altered expression of retinoblastoma (RB) protein in acute myelogenous leukemia does not result from methylation of the Rb promotor.

Kornblau SM, Qiu YH. Kornblau SM, et al. Leuk Lymphoma. 1999 Oct;35(3-4):283-8. doi: 10.3109/10428199909145731. Leuk Lymphoma. 1999. PMID: 10706451

8

The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia.

Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. Faderl S, et al. Among authors: kornblau sm. Cancer. 2000 Nov 1;89(9):1976-82. doi: 10.1002/1097-0142(20001101)89:9<1976::aid-cncr14>3.3.co;2-e. Cancer. 2000. PMID: 11064355

9

Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Giles F, et al. Invest New Drugs. 2001;19(1):13-20. doi: 10.1023/a:1006432012394. Invest New Drugs. 2001. PMID: 11291829 Clinical Trial.

10

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.

Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. Giles FJ, et al. Among authors: kornblau sm. Cancer. 2001 Jul 15;92(2):406-13. doi: 10.1002/1097-0142(20010715)92:2<406::aid-cncr1336>3.0.co;2-u. Cancer. 2001. PMID: 11466696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

354 results

Search Page

Filters